Forced Expiratory Volume in One Second as a Prognostic Factor in Advanced Non- small Cell Lung Cancer Jin Hwa Lee, MD, PhD, Eun Mi Song, MD, Yun Su Sim,

Slides:

Advertisements

Similar presentations

CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non–Small-Cell Lung Cancer in a Prospective Trial: CALGB Martin J. Edelman, MD, Lydia.

Advertisements

Curative Treatment of Stage I Non-Small-Cell Lung Cancer in Patients With Severe COPD: Stereotactic Radiotherapy Outcomes and Systematic Review David.

Su K. Metcalfe, MD, MPH, Michael T

Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

Sukki Cho, MD, Kyung-Min Ryu, MD, Yoon-Jin Hwang, MD, Eung Bae Lee, MD

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung Sai-Hong.

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis Ian Cromwell, MSc, Kimberly.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.

Sarah J. Gao, BS, Christopher D. Corso, MD, PhD, Elyn H

Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors

Brandon Stone, MD, Victor S. Mangona, MD, Matthew D

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.

Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer

The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer Kyong-Ah Yoon,

First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status Young Joo Lee, MD, Heung Tae Kim, MD,

Electronic Updates for JTO Readers

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

John E. Pilling, FRCS (CTh), Michael E

Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer Daniel Morgensztern, MD, Saiama.

Impact of the Maze operation on the progression of mild functional tricuspid regurgitation Hyung Gon Je, MD, Hyun Song, MD, Sung Ho Jung, MD, Suk Jung.

Successful Treatment with Crizotinib in Mechanically Ventilated Patients with ALK Positive Non–Small-Cell Lung Cancer Hee Kyung Ahn, MD, Kyeongman Jeon,

Leptomeningeal Carcinomatosis in Non–Small-Cell Lung Cancer Patients: Impact on Survival and Correlated Prognostic Factors Su Jin Lee, MD, Jung-Il Lee,

Prognostic Factors in Completely Resected Node-Negative Lung Adenocarcinoma of 3 cm or Smaller Jung-Jyh Hung, MD, PhD, Yi-Chen Yeh, MD, Yu-Chung Wu,

Frank Detterbeck, MD Journal of Thoracic Oncology

Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Positron Emission Tomography-Computed Tomography for Postoperative Surveillance in Non-Small Cell Lung Cancer Se Hoon Choi, MD, Young Tae Kim, MD, PhD,

Pretreatment Quality of Life Is an Independent Prognostic Factor for Overall Survival in Patients with Advanced Stage Non-small Cell Lung Cancer Yingwei.

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials Krista.

A Combined Prognostic Serum Interleukin-8 and Interleukin-6 Classifier for Stage 1 Lung Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening.

Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and.

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

Increasing Rates of No Treatment in Advanced-Stage Non–Small Cell Lung Cancer Patients: A Propensity-Matched Analysis Elizabeth A. David, MD, Megan E.

Does Granulocyte Colony–Stimulating Factor Affect Survival in Patients with Advanced Non-small Cell Lung Cancer? Goulnar Kasymjanova, MD, Harvey Kreisman,

Pharmacokinetics of Gefitinib Predicts Antitumor Activity for Advanced Non-small Cell Lung Cancer Yoichi Nakamura, MD, PhD, Kazumi Sano, PhD, Hiroshi.

Extratumoral Vascular Invasion Is a Significant Prognostic Indicator and a Predicting Factor of Distant Metastasis in Non-small Cell Lung Cancer Yoshihisa.

Survival Differences by Gender for Resected Non-small Cell Lung Cancer: A Retrospective Analysis of 12,509 Cases in a Japanese Lung Cancer Registry Study

Value of Combined Interpretation of Computed Tomography Response and Positron Emission Tomography Response for Prediction of Prognosis After Neoadjuvant.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Dose-per-Fraction Escalation of Accelerated Hypofractionated Three-Dimensional Conformal Radiotherapy in Locally Advanced Non-small Cell Lung Cancer

MTP13-01: Indications and limitations of bronchoscopy

Long-Term Results of Radiofrequency Ablation Treatment of Stage I Non-small Cell Lung Cancer: A Prospective Intention-to-Treat Study Marcello Carlo Ambrogi,

The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer Ryo Maeda, MD, Junji Yoshida, MD, PhD, Genichiro Ishii, MD, PhD,

Clinical Relevance of Our Multimodality Prognostic Score

It’s All in the “Swerve of the Curve”

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

A Phase II Study of Carboplatin, Etoposide, and Exisulind in Patients with Extensive Small Cell Lung Cancer: CALGB 30104 Ramaswamy Govindan, MD, Xiaofei.

Primary Small Cell Carcinoma of the Esophagus

Validity of International Association for the Study of Lung Cancer Proposals for the Revision of N Descriptors in Lung Cancer Jin Gu Lee, MD, Chang Young.

A Phase III Randomized Trial of Gemcitabine–Oxaliplatin versus Carboplatin–Paclitaxel as First-Line Therapy in Patients with Advanced Non-small Cell Lung.

Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non–Small- Cell Lung Cancer Jih-Hsiang Lee, MD, Yu-Lin Lin, MD, Wei-Hsun Hsu,

Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung.

Genetic and Proteomic Features Associated with Survival after Treatment with Erlotinib in First-Line Therapy of Non-small Cell Lung Cancer in Eastern.

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

A Review of First-Line Treatment for Small-cell Lung Cancer

Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD

Mark A. Socinski, MD Journal of Thoracic Oncology

Presentation transcript:

Forced Expiratory Volume in One Second as a Prognostic Factor in Advanced Non- small Cell Lung Cancer Jin Hwa Lee, MD, PhD, Eun Mi Song, MD, Yun Su Sim, MD, Yon Ju Ryu, MD, PhD, Jung Hyun Chang, MD, PhD Journal of Thoracic Oncology Volume 6, Issue 2, Pages 305-309 (February 2011) DOI: 10.1097/JTO.0b013e318201884b Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Kaplan-Meier survival curves. A, Forced expiratory volume in 1 second (FEV1) ≥ 50% predicted versus FEV1 less than 50% predicted. B, No chemotherapy versus chemotherapy. C, Nonadenocarcinoma versus adenocarcinoma. D, No malignant effusion versus malignant effusion. E, No radiotherapy versus radiotherapy. F, Male versus female. Tick marks indicate censored data. Journal of Thoracic Oncology 2011 6, 305-309DOI: (10.1097/JTO.0b013e318201884b) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions